| Description | Delavirdine mesylate (BHAP-U 90152 (mesylate)) is a non-nucleoside reverse transcriptase inhibitor (NNRTI). |
| In vitro | Delavirdine (mesylate) inhibits growth of clinical isolates of HIV-1 (ED50s = <0.005-0.69 μM). Delavirdine blocks replication of 25 primary HIV-1 isolates, including strains resistant to 3'-azido-2',3'-deoxythymidine (AZT) or 2',3'-dideoxyinosine, with a mean ED50 value of 0.066 μM. Delavirdine also inhibits growth of L. infantum promastigotes (IC50 = 26.1 μM)[1]. |
| Target activity | DNA polymerase α:440 μM (IC50), DNA polymerase δ:>550 μM (IC50), HIV-1 RT:0.26 μM (IC50) |
| Synonyms | U 90152 (mesylate), BHAP-U 90152 (mesylate), Delavirdine (mesylate) |
| molecular weight | 552.67 |
| Molecular formula | C23H32N6O6S2 |
| CAS | 147221-93-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 40.3 mg/mL (72.92 mM) |
| References | 1. Costa S , Machado M , Cavadas, Cláudia, et al. Antileishmanial activity of antiretroviral drugs combined with miltefosine[J]. Parasitology Research, 2016, 115(10):3881-3887. 2. Dueweke T J , Poppe S M , Romero D L , et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.[J]. Antimicrobial Agents and Chemotherapy, 1993, 37(5):1127-1131. |